Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Fever × dabrafenib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 30 Neoplasms 18 Carcinoma, Non-Small-Cell Lung 7 Skin Neoplasms 4 Neoplasm Metastasis 4 Glioma 4 Brain Neoplasms 4 Thyroid Carcinoma, Anaplastic 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurocytoma 2 Lung Neoplasms 2 Glioblastoma 2 Ganglioneuroma 2 Ganglioglioma 2 Astrocytoma 2 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Nonseminomatous germ cell tumor 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neuroblastoma 1 Multiple Myeloma 1 Melanoma, Cutaneous Malignant 1 Leukemia, Hairy Cell 1 Histiocytosis, Langerhans-Cell 1 Gastrointestinal Stromal Tumors 1 Fever 1 Differentiated Thyroid Cancer (DTC) 1

Interventions

pegfilgrastim 3 Vancomycin 2 trametinib 1 dabrafenib 1 ceftobiprole medocaril 1 Teicoplanin 1 Mannose-Binding Lectin 1 Itraconazole 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1 Cefepime 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03551626 2025-04-29

COMBI-APlus

Novartis

Phase 3 Completed

552 enrolled 12 charts

Fever, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡